MDGL · Madrigal Pharmaceuticals Inc
United States · RS rating 24 · As of 2026-10-14
| Price | 460.01 USD |
|---|---|
| 1-day change | +1.8% |
| RS rating (overall / 1M / 3M / 12M) | 24 / 20 / 24 / 57 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 37 / 22 / 44 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +49.4% |
| Sales growth Q/Q | +11.8% |
| Distance from 52-week high | +23.7% |
| Market cap (USD) | $11.9B |